HOME >> MEDICINE >> NEWS
Integrative Cancer Therapies journal accepted into prestigious ISI index

tice or Exercise Intervention? Studying the Benefit for Cancer Survivors"

"Extraction-Dependent Effects of American Ginseng (Panax quinquifolium) on Human Breast Cancer Cell Proliferation and Estrogen Receptor Activation"

Preadministration of High-Dose Salicylates, Suppressors of NF-kB Activation, May Increase the Chemosensitivity of Many Cancers

"Integrative cancer treatment incorporates the best of conventional interventions with meaningful, complementary therapies, and individualizes each patient's care regimen. Treatment plans may include chemotherapy, chronomodulated chemotherapy (circadian-timed chemotherapy), prescriptive exercise, nutritional pharmacology, scientifically tailored supplements, mind/body work and physical therapy," Dr. Block explains. "This acknowledgment by ISI will help professionals and patients alike understand ICT is a forum for disseminating information about groundbreaking and forward-looking work and I congratulate our editorial staff, editorial and advisory boards, and contributors to ICT for this important recognition."


'"/>

Contact: Judy Erickson
media.inquiries@sagepub.com
SAGE Publications
25-Sep-2006


Page: 1 2

Related medicine news :

1. Embargoed materials for Complementary & Integrative Medicine Conference
2. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
3. Cancer research summaries
4. Cancer on the agenda of the Portuguese EU Council Presidency
5. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
6. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
7. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
8. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
9. Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
10. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
11. Margaret Foti receives AACR Award for Leadership and Extraordinary Achievements in Cancer Research

Post Your Comments:
(Date:5/19/2013)... People in Minnesota have a great option ... offering its 28 Day Fat Loss Formula. The best ... of their own home. The product sells for $135 dollars ... be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is ... now, but after using the 28 Day Fat Loss Formula ...
(Date:5/19/2013)... New York, New York (PRWEB) May 19, 2013 ... move forward in a federal litigation now underway in ... to a Case Management Order dated May 3rd, the ... the Bellwether Nominee Pool to eight cases rather than ... litigation is scheduled for Thursday, May 23rd. (In re: ...
(Date:5/19/2013)... Park City, Utah (PRWEB) May 19, 2013 ... new information on small business health insurance ... alternatives to traditional employer sponsored health benefits, is ... contribution and health reimbursement arrangements . ... businesses, start-ups, and the self-employed intrinsically know the ...
(Date:5/19/2013)... According to a new market research ... – 2018): By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), ... Contact IS, Infrared, X-Ray) And Geography" published by ... $8.00 billion in 2012 and is expected to ... CAGR of 3.84% from 2013 to 2018. In ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 These ... for US, UK, Spain, Japan, Italy, Germany and ... the molecular diagnostics laboratory practice, as well as ... with significant market impact during the next five ... probe and biochip technologies, test formats, detection methodologies, ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4
(Date:5/18/2013)... YORK , May 18, 2013 ... law firm, is investigating potential securities fraud at ... AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... Company and its executives violated federal securities laws ... the Company,s Phase III drug trials for Tivopath ...
(Date:5/17/2013)... -- Medical devices are any medical items that are ... of their different mechanisms, actions and regulatory requirements, medical ... drug trails due to their unique clinical practices. Currently, ... both safety and efficacy (which is left to the ... as the SFDA) evaluate MDs for both safety and ...
(Date:5/17/2013)... 17, 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; ... Technology Small Business Technology Transfer Research (STTR) grant ... Infectious Diseases (NIAID), a division of the National ... novel human antibody therapeutics to combat Staphylococcus ... infections, including methicillin-resistant S. aureus (MRSA), ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4
Cached News: